Predicting the Progression of Very Early Systemic Sclerosis: Current Insights

References

• Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685–1699. doi:10.1016/S0140-6736(17)30933-9
   PubMed Web of Science ®Google Scholar
• Wielosz E, Majdan M. Clinical and serological parameters of progression and prognosis in patients with systemic sclerosis - a state of the art review. Wiad Lek. 2020;73(7):1528–1532.
   PubMedGoogle Scholar
• Yang C, Tang S, Zhu D, Ding Y, Qiao J. Classical disease-specific autoantibodies in systemic sclerosis: clinical features, gene susceptibility, and disease stratification. Front Med. 2020;7:587773. doi:10.3389/fmed.2020.587773
   Web of Science ®Google Scholar
• Bellando-Randone S, Matucci-Cerinic M. Very early systemic sclerosis. Best Pract Res Clin Rheumatol. 2019;33(4):101428. doi:10.1016/j.berh.2019.101428
   PubMed Web of Science ®Google Scholar
• LeRoy EC, Medsger TA. Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001;28(7):1573–1576.
   PubMed Web of Science ®Google Scholar
• Koenig M, Joyal F, Fritzler MJ, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud’s phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum. 2008;58(12):3902–3912. doi:10.1002/art.24038
   PubMed Web of Science ®Google Scholar
• Avouac J, Fransen J, Walker UA, et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis. 2011;70(3):476–481. doi:10.1136/ard.2010.136929
   PubMed Web of Science ®Google Scholar
• Minier T, Guiducci S, Bellando-Randone S, et al. Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Ann Rheum Dis. 2014;73(12):2087–2093. doi:10.1136/annrheumdis-2013-203716
   PubMed Web of Science ®Google Scholar
• van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747–1755. doi:10.1136/annrheumdis-2013-204424
   PubMed Web of Science ®Google Scholar
• Lepri G, Bellando Randone S, Matucci Cerinic M, Guiducci S. Early diagnosis of systemic sclerosis, where do we stand today? Expert Rev Clin Immunol. 2022;18(1):1–3. doi:10.1080/1744666X.2022.2015327
   PubMed Web of Science ®Google Scholar
• Bellando-Randone S, Galdo PFD, Lepri G, et al. Progression of patients with Raynaud’s phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS). Lancet Rheumatol. 2021;3(12):E834–843.
   Google Scholar
• Siqueira VS, Helbingen MFS, Medeiros-Ribeiro AC, et al. Predictors of progression to systemic sclerosis: analysis of Very Early Disease of Systemic Sclerosis (VEDOSS) in a large single cohort. Rheumatology. 2022. doi:10.1093/rheumatology/keac006
   PubMed Web of Science ®Google Scholar
• Valentini G, Vettori S, Cuomo G, et al. Early systemic sclerosis: short-term disease evolution and factors predicting the development of new manifestations of organ involvement. Arthritis Res Ther. 2012;14(4):R188. doi:10.1186/ar4019
   PubMed Web of Science ®Google Scholar
• Valentini G, Cuomo G, Abignano G, et al. Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features. Rheumatology. 2011;50(2):317–323. doi:10.1093/rheumatology/keq176
   PubMed Web of Science ®Google Scholar
• Lepri G, Guiducci S, Bellando-Randone S, et al. Evidence for oesophageal and anorectal involvement in very early systemic sclerosis (VEDOSS): report from a single VEDOSS/EUSTAR centre. Ann Rheum Dis. 2015;74(1):124–128. doi:10.1136/annrheumdis-2013-203889
   PubMed Web of Science ®Google Scholar
• Rodrigues GD, Tobaldini E, Bellocchi C, et al. Cardiac autonomic modulation at rest and during orthostatic stress among different systemic sclerosis subsets. Eur J Intern Med. 2019;66:75–80. doi:10.1016/j.ejim.2019.06.003
   PubMed Web of Science ®Google Scholar
• Matucci-Cerinic M, Bellando-Randone S, Lepri G, Bruni C, Guiducci S. Very early versus early disease: the evolving definition of the ‘many faces’ of systemic sclerosis. Ann Rheum Dis. 2013;72(3):319–321. doi:10.1136/annrheumdis-2012-202295
   PubMed Web of Science ®Google Scholar
• Walker UA, Tyndall A, Czirjak L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research group database. Ann Rheum Dis. 2007;66(6):754–763. doi:10.1136/ard.2006.062901
   PubMed Web of Science ®Google Scholar
• Jaeger VK, Wirz EG, Allanore Y, et al. Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a Longitudinal EUSTAR Study. PLoS One. 2016;11(10):e0163894. doi:10.1371/journal.pone.0163894
   PubMed Web of Science ®Google Scholar
• Diab S, Dostrovsky N, Hudson M, et al. Systemic sclerosis sine scleroderma: a multicenter study of 1417 subjects. J Rheumatol. 2014;41(11):2179–2185. doi:10.3899/jrheum.140236
   PubMed Web of Science ®Google Scholar
• Krieg T, Takehara K. Skin disease: a cardinal feature of systemic sclerosis. Rheumatology. 2009;48(Suppl 3):iii14–iii18. doi:10.1093/rheumatology/kep108
   PubMed Web of Science ®Google Scholar
• Domsic RT, Rodriguez-Reyna T, Lucas M, Fertig N, Medsger TA. Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. Ann Rheum Dis. 2011;70(1):104–109. doi:10.1136/ard.2009.127621
   PubMed Web of Science ®Google Scholar
• Medsger TA. Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheum Dis Clin North Am. 2003;29(2):255–73, vi. doi:10.1016/s0889-857x(03)00023-1
   PubMed Web of Science ®Google Scholar
• Steen V, Domsic RT, Lucas M, Fertig N, Medsger TA. A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis. Arthritis Rheum. 2012;64(9):2986–2994. doi:10.1002/art.34482
   PubMed Web of Science ®Google Scholar
• Volkmann ER, Furst DE. Management of systemic sclerosis-related skin disease: a review of existing and experimental therapeutic approaches. Rheum Dis Clin North Am. 2015;41(3):399–417. doi:10.1016/j.rdc.2015.04.004
   PubMed Web of Science ®Google Scholar
• Razykov I, Levis B, Hudson M, Baron M, Thombs BD; Canadian Scleroderma Research G. Prevalence and clinical correlates of pruritus in patients with systemic sclerosis: an updated analysis of 959 patients. Rheumatology. 2013;52(11):2056–2061. doi:10.1093/rheumatology/ket275
   PubMed Web of Science ®Google Scholar
• Ostojic P, Damjanov N, Pavlov-Dolijanovic S, Radunovic G. Peripheral vasculopathy in patients with systemic sclerosis: difference in limited and diffuse subset of disease. Clin Hemorheol Microcirc. 2004;31(4):281–285.
   PubMed Web of Science ®Google Scholar
• Muangchant C, Pope JE. The significance of interleukin-6 and C-reactive protein in systemic sclerosis: a systematic literature review. Clin Exp Rheumatol. 2013;31(2 Suppl 76):122–134.
   PubMed Web of Science ®Google Scholar
• Paik JJ, Wigley FM, Shah AA, et al. Association of fibrosing myopathy in systemic sclerosis and higher mortality. Arthritis Care Res. 2017;69(11):1764–1770. doi:10.1002/acr.23291
   Web of Science ®Google Scholar
• Terras S, Hartenstein H, Hoxtermann S, Gambichler T, Kreuter A. RNA polymerase III autoantibodies may indicate renal and more severe skin involvement in systemic sclerosis. Int J Dermatol. 2016;55(8):882–885. doi:10.1111/ijd.13032
   PubMed Web of Science ®Google Scholar
• Burbelo PD, Gordon SM, Waldman M, et al. Autoantibodies are present before the clinical diagnosis of systemic sclerosis. PLoS One. 2019;14(3):e0214202. doi:10.1371/journal.pone.0214202
   PubMed Web of Science ®Google Scholar
• Homer KL, Warren J, Karayev D, et al. Performance of anti-topoisomerase I antibody testing by multiple-bead, enzyme-linked immunosorbent assay and immunodiffusion in a university setting. J Clin Rheumatol. 2020;26(3):115–118. doi:10.1097/RHU.0000000000000971
   PubMed Web of Science ®Google Scholar
• Skaug B, Khanna D, Swindell WR, et al. Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. Ann Rheum Dis. 2020;79(3):379–386. doi:10.1136/annrheumdis-2019-215894
   PubMed Web of Science ®Google Scholar
• Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69(10):1809–1815. doi:10.1136/ard.2009.114264
   PubMed Web of Science ®Google Scholar
• Bernstein EJ, Jaafar S, Assassi S, et al. Performance characteristics of pulmonary function tests for the detection of interstitial lung disease in adults with early diffuse cutaneous systemic sclerosis. Arthritis Rheumatol. 2020;72(11):1892–1896. doi:10.1002/art.41415
   PubMed Web of Science ®Google Scholar
• Basta F, Afeltra A, Margiotta DPE. Fatigue in systemic sclerosis: a systematic review. Clin Exp Rheumatol. 2018;113(4):150–160.
   Google Scholar
• Peoples C, Medsger TA, Lucas M, Rosario BL, Feghali-Bostwick CA. Gender differences in systemic sclerosis: relationship to clinical features, serologic status and outcomes. J Scleroderma Relat Disord. 2016;1(2):177–240. doi:10.5301/jsrd.5000209
   PubMed Web of Science ®Google Scholar
• Smith V, Vanhaecke A, Guerra MG, et al. May capillaroscopy be a candidate tool in future algorithms for SSC-ILD: are we looking for the holy grail? A systematic review. Autoimmun Rev. 2020;19(9):102619. doi:10.1016/j.autrev.2020.102619
   PubMed Web of Science ®Google Scholar
• Muangchan C, Harding S, Khimdas S, et al. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group. Arthritis Care Res. 2012;64(9):1405–1414. doi:10.1002/acr.21716
   PubMed Web of Science ®Google Scholar
• Assassi S, Denton C, Cutolo M, et al. Effect of Nintedanib on KL-6 in patients with systemic sclerosis-associated interstitial lung disease [abstract]. Arthritis Rheumatol. 2021;6(suppl 10):248.
   Google Scholar
• Kuwana M, Shirai Y, Takeuchi T. Elevated serum krebs von den lungen-6 in early disease predicts subsequent deterioration of pulmonary function in patients with systemic sclerosis and interstitial lung disease. J Rheumatol. 2016;43(10):1825–1831. doi:10.3899/jrheum.160339
   PubMed Web of Science ®Google Scholar
• Volkmann ER, Tashkin DP, Kuwana M, et al. Progression of interstitial lung disease in systemic sclerosis: the importance of pneumoproteins Krebs von den Lungen 6 and CCL18. Arthritis Rheumatol. 2019;71(12):2059–2067. doi:10.1002/art.41020
   PubMed Web of Science ®Google Scholar
• Salazar GA, Kuwana M, Wu M, et al. KL-6 but not CCL-18 is a predictor of early progression in systemic sclerosis-related interstitial lung disease. J Rheumatol. 2018;45(8):1153–1158. doi:10.3899/jrheum.170518
   PubMed Web of Science ®Google Scholar
• Bonella F, Volpe A, Caramaschi P, et al. Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28(1):27–33.
   PubMed Web of Science ®Google Scholar
• Arron JR. Biomarkers in systemic sclerosis: mechanistic insights into pathogenesis and treatment. Curr Opin Rheumatol. 2021;33(6):480–485. doi:10.1097/BOR.0000000000000827
   PubMed Web of Science ®Google Scholar
• Ebata S, Yoshizaki A, Fukasawa T, Asano Y, Oba K, Sato S. Rapid decrease of serum surfactant protein-D levels predicts the reactivity of rituximab therapy in systemic sclerosis-associated interstitial lung disease. J Dermatol. 2020;47(7):796–800. doi:10.1111/1346-8138.15379
   PubMed Web of Science ®Google Scholar
• De Lauretis A, Sestini P, Pantelidis P, et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol. 2013;40(4):435–446. doi:10.3899/jrheum.120725
   PubMed Web of Science ®Google Scholar
• Khanna D, Lin CJF, Furst DE, et al. Long-term safety and efficacy of tocilizumab in early systemic sclerosis-interstitial lung disease: open-label extension of a Phase 3 randomized controlled trial. Am J Respir Crit Care Med. 2022;205(6):674–684. doi:10.1164/rccm.202103-0714OC
   PubMed Web of Science ®Google Scholar
• Khanna SA, Nance JW, Suliman SA. Detection and monitoring of interstitial lung disease in patients with systemic sclerosis. Curr Rheumatol Rep. 2022;24(5):166–173. doi:10.1007/s11926-022-01067-5
   PubMed Web of Science ®Google Scholar
• Desai SR, Veeraraghavan S, Hansell DM, et al. CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology. 2004;232(2):560–567. doi:10.1148/radiol.2322031223
   PubMed Web of Science ®Google Scholar
• Strollo D, Goldin J. Imaging lung disease in systemic sclerosis. Curr Rheumatol Rep. 2010;12(2):156–161. doi:10.1007/s11926-010-0095-0
   PubMedGoogle Scholar
• Chung JH, Walker CM, Hobbs S. Imaging features of systemic sclerosis-associated interstitial lung disease. J Vis Exp. 2020;(160). doi:10.3791/60300
   Web of Science ®Google Scholar
• Assassi S, Shao N, Yin Z, Volkmann ER, Zoz DF, Leonard TB. Understanding diagnostic pathways in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a retrospective cohort study. Medicine. 2022;101(32):e29993. doi:10.1097/MD.0000000000029993
   PubMed Web of Science ®Google Scholar
• Forman CJ, Olson SW, Gordon SM, et al. Association of race and risk of future scleroderma renal crisis at systemic sclerosis diagnosis. Arthritis Care Res. 2021. doi:10.1002/acr.24807
   Web of Science ®Google Scholar
• Woodworth TG, Suliman YA, Li W, Furst DE, Clements P. Scleroderma renal crisis and renal involvement in systemic sclerosis. Nat Rev Nephrol. 2016;12(11):678–691. doi:10.1038/nrneph.2016.124
   PubMed Web of Science ®Google Scholar
• Gordon SM, Stitt RS, Nee R, et al. Risk factors for future scleroderma renal crisis at systemic sclerosis diagnosis. J Rheumatol. 2019;46(1):85–92. doi:10.3899/jrheum.171186
   PubMed Web of Science ®Google Scholar
• Hudson M, Ghossein C, Steen V. Scleroderma renal crisis. Presse Med. 2021;50(1):104063. doi:10.1016/j.lpm.2021.104063
   PubMed Web of Science ®Google Scholar
• Butt SA, Jeppesen JL, Torp-Pedersen C, et al. Cardiovascular manifestations of systemic sclerosis: a Danish Nationwide Cohort Study. J Am Heart Assoc. 2019;8(17):e013405. doi:10.1161/JAHA.119.013405
   PubMed Web of Science ®Google Scholar
• Lambova S. Cardiac manifestations in systemic sclerosis. World J Cardiol. 2014;6(9):993–1005. doi:10.4330/wjc.v6.i9.993
   PubMedGoogle Scholar
• Hachulla AL, Launay D, Gaxotte V, et al. Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Ann Rheum Dis. 2009;68(12):1878–1884. doi:10.1136/ard.2008.095836
   PubMed Web of Science ®Google Scholar
• de Groote P, Gressin V, Hachulla E, et al. Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis. Ann Rheum Dis. 2008;67(1):31–36. doi:10.1136/ard.2006.057760
   PubMed Web of Science ®Google Scholar
• Vacca A, Meune C, Gordon J, et al. Cardiac arrhythmias and conduction defects in systemic sclerosis. Rheumatology. 2014;53(7):1172–1177. doi:10.1093/rheumatology/ket377
   PubMed Web of Science ®Google Scholar
• Bruni C, Ross L. Cardiac involvement in systemic sclerosis: getting to the heart of the matter. Best Pract Res Clin Rheumatol. 2021;35(3):101668. doi:10.1016/j.berh.2021.101668
   PubMed Web of Science ®Google Scholar
• Bayar N, Cay HF, Erkal Z, et al. The importance of fragmented QRS in the early detection of cardiac involvement in patients with systemic sclerosis. Anatol J Cardiol. 2015;15(3):209–212. doi:10.5152/akd.2014.5191
   PubMed Web of Science ®Google Scholar
• Kadi H, Inanir A, Habiboglu A, et al. Frequency of fragmented QRS on ECG is increased in patients with rheumatoid arthritis without cardiovascular disease: a pilot study. Mod Rheumatol. 2012;22(2):238–242. doi:10.1007/s10165-011-0493-9
   PubMed Web of Science ®Google Scholar
• Basaran Y, Tigen K, Karaahmet T, et al. Fragmented QRS complexes are associated with cardiac fibrosis and significant intraventricular systolic dyssynchrony in nonischemic dilated cardiomyopathy patients with a narrow QRS interval. Echocardiography. 2011;28(1):62–68. doi:10.1111/j.1540-8175.2010.01242.x
   PubMed Web of Science ®Google Scholar
• Mavrogeni SI, Bratis K, Karabela G, et al. Cardiovascular magnetic resonance imaging clarifies cardiac pathophysiology in early, asymptomatic diffuse systemic sclerosis. Inflamm Allergy Drug Targets. 2015;14(1):29–36. doi:10.2174/1871528114666150916112551
   PubMedGoogle Scholar
• Foocharoen C, Pussadhamma B, Mahakkanukrauh A, Suwannaroj S, Nanagara R. Asymptomatic cardiac involvement in Thai systemic sclerosis: prevalence and clinical correlations with non-cardiac manifestations (preliminary report). Rheumatology. 2015;54(9):1616–1621. doi:10.1093/rheumatology/kev096
   PubMed Web of Science ®Google Scholar
• Pussadhamma B, Mahakkanukrauh A, Suwannaroj S, Nanagara R, Foocharoen C. Clinical outcomes of asymptomatic cardiac involvement in systemic sclerosis patients after a 2-year follow-up (extended study). Am J Med Sci. 2021;362(6):570–577. doi:10.1016/j.amjms.2021.05.027
   PubMed Web of Science ®Google Scholar
• Lefevre G, Dauchet L, Hachulla E, et al. Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis. Arthritis Rheum. 2013;65(9):2412–2423. doi:10.1002/art.38029
   PubMed Web of Science ®Google Scholar
• Ramjug S, Hussain N, Hurdman J, et al. Idiopathic and systemic sclerosis-associated pulmonary arterial hypertension: a comparison of demographic, hemodynamic, and MRI characteristics and outcomes. Chest. 2017;152(1):92–102. doi:10.1016/j.chest.2017.02.010
   PubMed Web of Science ®Google Scholar
• Chaisson NF, Hassoun PM. Systemic sclerosis-associated pulmonary arterial hypertension. Chest. 2013;144(4):1346–1356. doi:10.1378/chest.12-2396
   PubMed Web of Science ®Google Scholar
• Hachulla E, Launay D, Mouthon L, et al. Is pulmonary arterial hypertension really a late complication of systemic sclerosis? Chest. 2009;136(5):1211–1219. doi:10.1378/chest.08-3042
   PubMed Web of Science ®Google Scholar
• Krikeerati T, Pussadhamma B, Mahakkanukrauh A, Suwannaroj S, Nanagara R, Foocharoen C. Associated factors of early-onset pulmonary hypertension and clinical difference between early- and late-onset pulmonary hypertension in Thai systemic sclerosis. Mod Rheumatol. 2021;31(3):649–656. doi:10.1080/14397595.2020.1823067
   PubMed Web of Science ®Google Scholar
• Coirier V, Chabanne C, Jouneau S, et al. Impact of three different algorithms for the screening of SSc-PAH and comparison with the decisions of a multidisciplinary team. Diagnostics. 2021;11(10). doi:10.3390/diagnostics11101738
   Web of Science ®Google Scholar
• McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009;119(16):2250–2294. doi:10.1161/CIRCULATIONAHA.109.192230
   PubMed Web of Science ®Google Scholar
• Brown Z, Proudman S, Morrisroe K, Stevens W, Hansen D, Nikpour M. Screening for the early detection of pulmonary arterial hypertension in patients with systemic sclerosis: a systematic review and meta-analysis of long-term outcomes. Semin Arthritis Rheum. 2021;51(3):495–512. doi:10.1016/j.semarthrit.2021.03.011
   PubMed Web of Science ®Google Scholar
• Bauer Y, de Bernard S, Hickey P, et al. Identifying early pulmonary arterial hypertension biomarkers in systemic sclerosis: machine learning on proteomics from the DETECT cohort. Eur Respir J. 2021;57(6). doi:10.1183/13993003.02591-2020
   Web of Science ®Google Scholar
• McMahan ZH. Gastrointestinal involvement in systemic sclerosis: an update. Curr Opin Rheumatol. 2019;31(6):561–568. doi:10.1097/BOR.0000000000000645
   PubMed Web of Science ®Google Scholar
• Petcu A, Ghib LJ, Grad SM, et al. Upper gastrointestinal involvement in systemic sclerosis: findings in a real-life setting. Exp Ther Med. 2019;18(6):5095–5100. doi:10.3892/etm.2019.8125
   PubMed Web of Science ®Google Scholar
• El-Gendy H, Shohdy KS, Maghraby GG, Abadeer K, Mahmoud M. Gastric antral vascular ectasia in systemic sclerosis: where do we stand? Int J Rheum Dis. 2017;20(12):2133–2139. doi:10.1111/1756-185X.13047
   PubMed Web of Science ®Google Scholar
• Hung EW, Mayes MD, Sharif R, et al. Gastric antral vascular ectasia and its clinical correlates in patients with early diffuse systemic sclerosis in the Scot trial. J Rheumatol. 2013;40(4):455–460. doi:10.3899/jrheum.121087
   PubMed Web of Science ®Google Scholar
• Christmann RB, Wells AU, Capelozzi VL, Silver RM. Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence. Semin Arthritis Rheum. 2010;40(3):241–249. doi:10.1016/j.semarthrit.2010.03.002
   PubMed Web of Science ®Google Scholar
• Savarino E, Bazzica M, Zentilin P, et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am J Respir Crit Care Med. 2009;179(5):408–413. doi:10.1164/rccm.200808-1359OC
   PubMed Web of Science ®Google Scholar
• Volkmann E, Tashkin D, Leng M, Kim G, Goldin J, Roth M. Symptoms of Gastroesophageal reflux are a better predictor of systemic sclerosis-related interstitial lung disease progression than quantitative radiographic assessment of esophageal paramters [Abstract]. Ann Rheum Dis. 2022;81:718–719.
   Web of Science ®Google Scholar
• Wangkaew S, Losuriya P, Euathrongchit J. Worsening of esophageal dilatation is associated with increase in a high-resolution computed tomography (HRCT) score in early systemic sclerosis-associated interstitial lung disease (SSc-ILD). Clin Rheumatol. 2021;40(3):955–963. doi:10.1007/s10067-020-05346-3
   PubMed Web of Science ®Google Scholar
• Wigley FM, Flavahan NA. Raynaud’s Phenomenon. N Engl J Med. 2016;375(6):556–565. doi:10.1056/NEJMra1507638
   PubMed Web of Science ®Google Scholar
• Herrick AL, Wigley FM. Raynaud’s phenomenon. Best Pract Res Clin Rheumatol. 2020;34(1):101474. doi:10.1016/j.berh.2019.101474
   PubMed Web of Science ®Google Scholar
• Maricq HR, LeRoy EC. Patterns of finger capillary abnormalities in connective tissue disease by “wide-field” microscopy. Arthritis Rheum. 1973;16(5):619–628. doi:10.1002/art.1780160506
   PubMed Web of Science ®Google Scholar
• Cutolo M, Sulli A, Pizzorni C, Accardo S. Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol. 2000;27(1):155–160.
   PubMed Web of Science ®Google Scholar
• Hachulla E, Clerson P, Launay D, et al. Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. J Rheumatol. 2007;34(12):2423–2430.
   PubMed Web of Science ®Google Scholar
• Silva I, Teixeira A, Oliveira J, et al. Endothelial dysfunction and nailfold videocapillaroscopy pattern as predictors of digital ulcers in systemic sclerosis: a cohort study and review of the literature. Clin Rev Allergy Immunol. 2015;49(2):240–252. doi:10.1007/s12016-015-8500-0
   PubMed Web of Science ®Google Scholar
• Lambova SN, Muller-Ladner U. Nailfold capillaroscopy in systemic sclerosis - state of the art: the evolving knowledge about capillaroscopic abnormalities in systemic sclerosis. J Scleroderma Relat Disord. 2019;4(3):200–211. doi:10.1177/2397198319833486
   PubMed Web of Science ®Google Scholar
• Denton CP, Krieg T, Guillevin L, et al. Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry. Ann Rheum Dis. 2012;71(5):718–721. doi:10.1136/annrheumdis-2011-200631
   PubMed Web of Science ®Google Scholar
• Acosta-Herrera M, Kerick M, Lopez-Isac E, et al. Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes. Ann Rheum Dis. 2021. doi:10.1136/annrheumdis-2021-219884
   Web of Science ®Google Scholar
• Angiolilli C, Marut W, van der Kroef M, Chouri E, Reedquist KA, Radstake T. New insights into the genetics and epigenetics of systemic sclerosis. Nat Rev Rheumatol. 2018;14(11):657–673. doi:10.1038/s41584-018-0099-0
   PubMed Web of Science ®Google Scholar
• Xu Y, Wang W, Tian Y, Liu J, Yang R. Polymorphisms in STAT4 and IRF5 increase the risk of systemic sclerosis: a meta-analysis. Int J Dermatol. 2016;55(4):408–416. doi:10.1111/ijd.12839
   PubMed Web of Science ®Google Scholar
• Lopez-Isac E, Martin JE, Assassi S, et al. Brief report: IRF4 newly identified as a common susceptibility locus for systemic sclerosis and rheumatoid arthritis in a cross-disease meta-analysis of genome-wide association studies. Arthritis Rheumatol. 2016;68(9):2338–2344. doi:10.1002/art.39730
   PubMed Web of Science ®Google Scholar
• Assassi S, Volkmann ER, Zheng WJ, et al. Peripheral blood gene expression profiling shows predictive significance for response to mycophenolate in systemic sclerosis-related interstitial lung disease. Ann Rheum Dis. 2022;81(6):854–860. doi:10.1136/annrheumdis-2021-221313
   PubMed Web of Science ®Google Scholar
• Skaug B, Lyons MA, Swindell WR, et al. Large-scale analysis of longitudinal skin gene expression in systemic sclerosis reveals relationships of immune cell and fibroblast activity with skin thickness and a trend towards normalisation over time. Ann Rheum Dis. 2022;81(4):516–523. doi:10.1136/annrheumdis-2021-221352
   PubMed Web of Science ®Google Scholar
• Brkic Z, van Bon L, Cossu M, et al. The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis. Ann Rheum Dis. 2016;75(8):1567–1573. doi:10.1136/annrheumdis-2015-207392
   PubMed Web of Science ®Google Scholar
• Vettori S, Cuomo G, Iudici M, et al. Early systemic sclerosis: serum profiling of factors involved in endothelial, T-cell, and fibroblast interplay is marked by elevated interleukin-33 levels. J Clin Immunol. 2014;34(6):663–668. doi:10.1007/s10875-014-0037-0
   PubMed Web of Science ®Google Scholar
• Cossu M, van Bon L, Nierkens S, et al. The magnitude of cytokine production by stimulated CD56(+) cells is associated with early stages of systemic sclerosis. Clin Immunol. 2016;173:76–80. doi:10.1016/j.clim.2016.09.004
   PubMed Web of Science ®Google Scholar
• Cossu M, van Bon L, Preti C, Rossato M, Beretta L, Radstake T. Earliest Phase of systemic sclerosis typified by increased levels of inflammatory proteins in the serum. Arthritis Rheumatol. 2017;69(12):2359–2369. doi:10.1002/art.40243
   PubMed Web of Science ®Google Scholar
• Crescioli C, Corinaldesi C, Riccieri V, et al. Association of circulating CXCL10 and CXCL11 with systemic sclerosis. Ann Rheum Dis. 2018;77(12):1845–1846. doi:10.1136/annrheumdis-2018-213257
   PubMed Web of Science ®Google Scholar
• Distler O, Del Rosso A, Giacomelli R, et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res. 2002;4(6):R11. doi:10.1186/ar596
   PubMedGoogle Scholar
• Almeida I, Oliveira Gomes A, Lima M, Silva I, Vasconcelos C. Different contributions of angiostatin and endostatin in angiogenesis impairment in systemic sclerosis: a cohort study. Clin Exp Rheumatol. 2016;100(5):37–42.
   Google Scholar
• Chora I, Romano E, Manetti M, et al. Evidence for a derangement of the microvascular system in patients with a very early diagnosis of systemic sclerosis. J Rheumatol. 2017;44(8):1190–1197. doi:10.3899/jrheum.160791
   PubMed Web of Science ®Google Scholar
• Romano E, Manetti M, Rosa I, et al. Slit2/Robo4 axis may contribute to endothelial cell dysfunction and angiogenesis disturbance in systemic sclerosis. Ann Rheum Dis. 2018;77(11):1665–1674. doi:10.1136/annrheumdis-2018-213239
   PubMed Web of Science ®Google Scholar
• Jiang Z, Chen C, Yang S, He H, Zhu X, Liang M. Contribution to the peripheral vasculopathy and endothelial cell dysfunction by CXCL4 in Systemic Sclerosis. J Dermatol Sci. 2021;104(1):63–73. doi:10.1016/j.jdermsci.2021.07.006
   PubMed Web of Science ®Google Scholar
• Bellocchi C, Volkmann ER. Update on the gastrointestinal microbiome in systemic sclerosis. Curr Rheumatol Rep. 2018;20(8):49. doi:10.1007/s11926-018-0758-9
   PubMed Web of Science ®Google Scholar
• Seksik P, Rigottier-Gois L, Gramet G, et al. Alterations of the dominant faecal bacterial groups in patients with Crohn’s disease of the colon. Gut. 2003;52(2):237–242. doi:10.1136/gut.52.2.237
   PubMed Web of Science ®Google Scholar
• Chen BD, Jia XM, Xu JY, et al. An autoimmunogenic and proinflammatory profile defined by the gut microbiota of patients with untreated systemic lupus erythematosus. Arthritis Rheumatol. 2021;73(2):232–243. doi:10.1002/art.41511
   PubMed Web of Science ®Google Scholar
• Bellocchi C, Fernandez-Ochoa A, Montanelli G, et al. Identification of a shared microbiomic and metabolomic profile in systemic autoimmune diseases. J Clin Med. 2019;8(9). doi:10.3390/jcm8091291
   PubMed Web of Science ®Google Scholar
• Bellocchi C, Fernandez-Ochoa A, Montanelli G, et al. Microbial and metabolic multi-omic correlations in systemic sclerosis patients. Ann N Y Acad Sci. 2018;1421(1):97–109. doi:10.1111/nyas.13736
   PubMed Web of Science ®Google Scholar
• Andreasson K, Alrawi Z, Persson A, Jonsson G, Marsal J. Intestinal dysbiosis is common in systemic sclerosis and associated with gastrointestinal and extraintestinal features of disease. Arthritis Res Ther. 2016;18(1):278. doi:10.1186/s13075-016-1182-z
   PubMed Web of Science ®Google Scholar
• Patrone V, Puglisi E, Cardinali M, et al. Gut microbiota profile in systemic sclerosis patients with and without clinical evidence of gastrointestinal involvement. Sci Rep. 2017;7(1):14874. doi:10.1038/s41598-017-14889-6
   PubMed Web of Science ®Google Scholar
• Levin D, De Palma G, Zou H, et al. Fecal microbiome differs between patients with systemic sclerosis with and without small intestinal bacterial overgrowth. J Scleroderma Relat Disord. 2021;6(3):290–298. doi:10.1177/23971983211032808
   PubMed Web of Science ®Google Scholar
• Andreasson K, Lee SM, Lagishetty V, et al. Disease features and gastrointestinal microbial composition in patients with systemic sclerosis from two independent cohorts. ACR Open Rheumatol. 2022;4(5):417–425. doi:10.1002/acr2.11387
   PubMedGoogle Scholar
• Dobrev H. Novel ideas: the increased skin viscoelasticity - a possible new fifth sign for the very early diagnosis of systemic sclerosis. Curr Rheumatol Rev. 2013;9(4):261–267. doi:10.2174/157339710904140417125455
   PubMedGoogle Scholar
• Dobrev H. In vivo study of skin mechanical properties in Raynaud’s phenomenon. Skin Res Technol. 2007;13(1):91–94. doi:10.1111/j.1600-0846.2007.00197.x
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Lucas M, Fertig N, Oddis CV, Medsger TA. Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum. 2009;60(4):1112–1118. doi:10.1002/art.24409
   PubMed Web of Science ®Google Scholar
• Fertig N, Domsic RT, Rodriguez-Reyna T, et al. Anti-U11/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis. Arthritis Rheum. 2009;61(7):958–965. doi:10.1002/art.24586
   PubMed Web of Science ®Google Scholar
• Hoa S, Hudson M, Troyanov Y, et al. Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: clinical associations. Medicine. 2016;95(35):e4713. doi:10.1097/MD.0000000000004713
   PubMed Web of Science ®Google Scholar
• Koschik RW, Fertig N, Lucas MR, Domsic RT, Medsger TA. Anti-PM-Scl antibody in patients with systemic sclerosis. Clin Exp Rheumatol. 2012;30(2 Suppl 71):S12–6.
   PubMed Web of Science ®Google Scholar
• Wielosz E, Dryglewska M, Majdan M. The prevalence and significance of anti-PM/Scl antibodies in systemic sclerosis. Ann Agric Environ Med. 2021;28(1):189–192. doi:10.26444/aaem/127801
   PubMed Web of Science ®Google Scholar
• Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K. The prevalence and clinical significance of anti-U1 RNA antibodies in patients with systemic sclerosis. J Invest Dermatol. 2003;120(2):204–210. doi:10.1046/j.1523-1747.2003.12028.x
   PubMed Web of Science ®Google Scholar
• Ihn H, Yamane K, Yazawa N, et al. Distribution and antigen specificity of anti-U1RNP antibodies in patients with systemic sclerosis. Clin Exp Immunol. 1999;117(2):383–387. doi:10.1046/j.1365-2249.1999.00961.x
   PubMed Web of Science ®Google Scholar